Last updated on January 2019
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Brief description of study
In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors that have progressed on standard of care therapy will be treated with pembrolizumab.
Clinical Study Identifier: NCT02628067
Start Over
Connect »
Connect »
Connect »
Connect »
Connect »
Connect »
Connect »
Connect »
Connect »
Connect »
Connect »
Connect »
Connect »
Connect »
Connect »
Connect »
Connect »
Connect »
Connect »
Connect »
Connect »
Connect »
Connect »
Connect »
Connect »
Connect »
Connect »
Connect »
Connect »
Connect »
Connect »
Connect »
Connect »
Connect »
Connect »